# Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

> **NCT02048618** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 175 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** GLPG0634
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02048618
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-11
- **Final completion:** 2016-02
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2016-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048618, "Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02048618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*